/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments.
$1.04
$0.02 (-1.89%)
EOD Sep 18, 2026
Negative free cash flow of -$25M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$17M
▲ +30.9% YoY
Op. Margin
—
ROIC
-85.53%
▲ +51.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$18M
▲ +13.7% YoY
Op. Cash Flow (TTM)
-$18M
▲ +13.6% YoY
Net Debt
-$34M
Net Cash Position
Cash & Equiv.
$34M
Continue Research
SourceComputed from the 10-Q filed 7 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 8 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.